Biostem Technologies

Biostem Technologies Current Assets

The Current Assets of Biostem Technologies (BSEM) as of Oct 4, 2026 is 110.93 M USD. In the previous year, Current Assets was 12.36 M USD — a change of 797.51% (higher).

Current Assets

110.93 MUSD

YoY

797.51%

Last updated:

Current Assets of Biostem Technologies is 2026 110.93 M USD. Current Assets of Biostem Technologies was 2025 12.36 M USD. It decreases by 797.51% higher compared to the previous year.

The Biostem Technologies Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2017
166,579.00 USD
Jan 1, 2018
415,031.00 USD
Jan 1, 2019
565,001.00 USD
Jan 1, 2020
580,990.00 USD
Jan 1, 2021
598,131.00 USD
Jan 1, 2022
677,160.00 USD
Jan 1, 2023
12.36 M USD
Jan 1, 2024
110.93 M USD
The Biostem Technologies Current Assets history
YEARCurrent AssetsYoY
110.93 MUSD+797.51%
12.36 MUSD+1,725.21%
677,160.00USD+13.21%
598,131.00USD+2.95%
580,990.00USD+2.83%
565,001.00USD+36.13%
415,031.00USD+149.15%
166,579.00USD+34.51%
123,837.00USD-66.77%
372,668.00USD—
0.00USD-100.00%
236,800.00USD+294.67%
60,000.00USD+20.00%
50,000.00USD—
0.00USD-100.00%
578,027.00USD—
0.00USD—
Access this data via the Eulerpool API

Biostem Technologies Stock analysis

What does Biostem Technologies do? Biostem Technologies Inc is a US company specializing in regenerative medicine. It was founded in 2007 and is based in Clearwater, Florida. Biostem Technologies is listed on the OTCQB Stock Exchange and offers a wide range of products in the field of regenerative medicine. The company's business model primarily involves advancing growth in the field of regenerative medicine through the development and marketing of new products and technologies. They focus on the production of stem cells that can be used in the regeneration of damaged tissues and organs. They also offer research and development of stem cell therapies, manufacturing of stem cell products, and related services. Biostem Technologies places emphasis on processing umbilical cord blood stem cells, collaborating with medical facilities to collect and isolate these cells for preservation. The company has also developed products such as BioStem Serum and BioStem Gel, made from stem cells and used in regeneration and wound healing. They have developed technologies for regenerating damaged tissues and organs, including a technology for regenerating muscle and adipose tissue through stem cell injection. Clinical studies have shown promising results with this technology. Biostem Technologies has partnerships with other companies and institutes in the field of regenerative medicine, including working with the National Institute of Neurological Disorders and Stroke to develop a new therapy for multiple sclerosis. They also provide consulting services to assist other companies in developing regenerative products and services. In conclusion, Biostem Technologies is a leading company in the field of regenerative medicine and stem cell therapies, offering a range of products and services. They also provide important technologies for tissue regeneration, positioning them as a key player in the field of regenerative medicine. Biostem Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biostem Technologies stock

Current Assets of Biostem Technologies is 110.93 M USD in 2026.

Current Assets of Biostem Technologies changed from 12.36 M USD to 110.93 M USD, representing a 797.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Biostem Technologies since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Biostem Technologies historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Biostem Technologies

All Key Metrics — Biostem Technologies